Drug news
FDA Panel recommends Cimzia for Axial Spondyloarthritis
UCB announced the outcome from their participation in the FDA�s Arthritis Advisory Committee to discuss its supplemental biologics application (sBLA) for Cimzia (certolizumab pegol) for the proposed indication of treatment of adults with active Axial Spondyloarthritis (axSpA), including patients with ankylosing spondylitis (AS). The Arthritis Advisory Committee voted seven to six, with one Committee member abstaining, to recommend approval of Cimzia for the proposed indication.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins